Physician profile

Robert Chadband

Endocrinology, Diabetes & Metabolism · Cullman, AL

NPI 1134181431

$2,322.60

in general payments reported to CMS, 2019-2025

33 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Amarin Pharma, INC. $469.35 2019-2022
Amgen INC. $249.40 2019-2022
Astrazeneca Pharmaceuticals LP $148.25 2020-2021
Lilly USA, LLC $144.30 2020-2022
Sanofi-Aventis U.S. LLC $134.55 2019-2020
Medtronic, INC. $133.56 2021-2022
Medtronic Minimed, INC. $117.48 2020
Corcept Therapeutics $101.07 2019-2021
Xeris Pharmaceuticals, INC. $83.89 2021-2022
Abbvie INC. $69.10 2021-2022
Merck Sharp & Dohme LLC $59.44 2019-2021
Ibsa Pharma INC. $53.77 2020
Boehringer Ingelheim Pharmaceuticals, INC. $50.89 2019-2021
Grifols USA, LLC $48.41 2021
Janssen Pharmaceuticals, INC $38.65 2019-2020
Show all 33 companies

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Robert Chadband

$2,322.60

in general payments reported 2019-2025

Years
2019-2022
Top company
Amarin Pharma, INC.

https://glasscript.com/doctor/323241/robert-chadband

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.